To investigate the ability of cerebrospinal fluid (CSF) and plasma measures to discriminate early-stage Alzheimer disease (AD) (defined by clinical criteria and presence/absence of brain amyloid) from nondemented aging and to assess whether these biomarkers can predict future dementia in cognitively normal individuals. Results: Individuals with very mild or mild AD have reduced mean levels of CSF A␤ 42 and increased levels of CSF tau and phosphorylated tau 181 . Cerebrospinal fluid A␤ 42 level completely corresponds with the presence or absence of brain amyloid (imaged with Pittsburgh Compound B) in demented and nondemented individuals. The CSF tau/A␤ 42 ratio (adjusted hazard ratio, 5.21; 95% confidence interval, 1.58-17.22) and phosphorylated tau 181 /A␤ 42 ratio (adjusted hazard ratio, 4.39; 95% confidence interval, 1.62-11.86) predict conversion from a CDR of 0 to a CDR greater than 0.
W
ITHOUT TRULY EFfective therapies, Alzheimer disease (AD) will soon become a public health crisis. Biological markers are essential to aid in the development of diseasemodifying therapies and identify individuals at high risk or in the earliest clinical stages. Alzheimer disease pathologic abnormalities (amyloid plaques, neurofibrillary tangles) appear to begin 10 to 20 years before cognitive symptoms or significant neuronal loss. [1] [2] [3] [4] [5] Thus, it is critical to identify affected individuals while they are still cognitively normal (preclinical AD), prior to overt synaptic and neuronal loss, so new therapies have a chance to preserve normal brain function.
Analytes in cerebrospinal fluid (CSF) have shown promise in discriminating individuals with AD from nondemented aging. Mean levels of CSF ␤-amyloid 42 (A␤ 42 ) (forming amyloid plaques) typically decrease in AD whereas levels of CSF tau (forming neurofibrillary tangles) increase. 6 However, overlap between demented and nondemented groups has limited the diagnostic potential of these markers. This overlap may represent biological variability, inaccurate diagnostic classification, or both. Reductions in CSF A␤ 42 may result from a "sink" effect of A␤ 42 -containing plaques. 7 Currently, a definitive diagnosis of AD is possible only at autopsy. Some individuals with clinical diagnoses of AD may be misdiagnosed and have high levels of CSF A␤ 42 because they lack amyloid deposition. Some who are cognitively normal may have low CSF A␤ 42 levels due to the presence of amyloid prior to dementia (preclinical AD).
To address these issues, we investigated the ability of CSF and plasma markers to discriminate early-stage AD cohorts defined by clinical criteria as well as the presence or absence of brain amyloid (via positron emission tomographic imaging of Pittsburgh Compound B [PIB]) 8 from nondemented aging. We also assessed whether these biomarkers could predict future dementia in cognitively normal elders.
METHODS

PARTICIPANTS
Participants were community-dwelling volunteers enrolled in longitudinal studies of healthy aging and dementia through the Washington University Alzheimer Disease Research Center. Participants were 60 to 91 years of age and in good general health; they had no other neurological, psychiatric, or systemic medical illness that could contribute importantly to dementia nor medical contraindication to lumbar puncture (LP). Cognitive status was determined annually in accordance with standard protocols and criteria. 9, 10 A Clinical Dementia Rating (CDR) 11 of 0 indicated no dementia whereas CDR 0.5 and CDR 1 indicated very mild and mild AD dementia, respectively, based on criteria from the National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer's Disease and Related Disorders Association. 12 The rate of postmortem confirmation of AD clinical diagnosis in our center is 93%, 10 including the CDR 0.5 stage. Studies were approved by the human studies committee at Washington University, and written informed consent was obtained from all participants. Apolipoprotein E (APOE ) genotypes were provided by the Alzheimer Disease Research Center Genetics Core (A. Goate, DPhil, core leader).
CSF AND PLASMA COLLECTION, PROCESSING, AND ASSESSMENT
Cerebrospinal fluid (20-30 mL) was collected at 8 AM after overnight fasting. Samples were gently inverted to avoid possible gradient effects, briefly centrifuged at low speed, and aliquoted into polypropylene tubes prior to freezing at −84°C. 13 Fasted blood was obtained at the time of LP and collected into polypropylene tubes containing ethylenediaminetetraacetic acid. Plasma was prepared by standard centrifugation methods prior to aliquoting and freezing at −84°C.
Cerebrospinal fluid samples were analyzed for total tau, phosphorylated tau 181 (ptau 181 ), and A␤ 42 by enzyme-linked immunosorbant assay (Innotest; Innogenetics, Ghent, Belgium). Cerebrospinal fluid A␤ 40 and plasma A␤ 40 and A␤ 42 were assayed by enzyme-linked immunosorbant assay.
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IN VIVO AMYLOID IMAGING WITH PIB
Fifty of 139 participants underwent in vivo amyloid imaging via PIB positron emission tomography within 2 years of LP as described. 7 Presence of cortical amyloid was defined by a mean cortical PIB binding potential of 0.2 or more (averaging prefrontal cortex, precuneus, lateral temporal cortex, and gyrus rectus).
STATISTICAL ANALYSES
Analyses were performed by the Alzheimer Disease Research Center Biostatistics Core (P. Miller, AB, core leader) using SAS version 9.1 for Sun OS (SAS Inc, Cary, NC). General linear models examined whether biomarker values differed by CDR. Clinical Dementia Rating, age, sex, education, APOE genotype (presence vs absence of an ε4 allele), and all possible 2-and 3-factor interaction terms were included in the models. Independent t tests, single-factor analysis of variance, or 2 analyses tested whether unadjusted biomarker and demographic variables differed among groups. Receiver operating characteristic curve analyses assessed biomarker sensitivity and specificity for discriminating clinical groups. To assess predictors of future dementia in nondemented participants, Cox proportional hazards models tested the effect of demographic and biomarker variables on the rate of receiving a CDR greater than 0 in individuals who had a CDR of 0 at the time of LP and had 1 or more follow-up clinical assessments. Follow-up times for participants retaining a CDR greater than 0 were considered statistically censored on the date of their last assessment. Statistical significance was defined by PϽ.05.
RESULTS
DEMOGRAPHICS OF NONDEMENTED AND EARLY AD COHORTS
We compared CSF biomarker data from cognitively normal subjects (CDR 0) with those of subjects with very mild (CDR 0.5) or mild (CDR 1) AD. Demographic characteristics of 139 participants are described in Table 1 . The groups did not differ significantly with regard to age at LP. However, they did differ in (1) mean educational level, with CDR 1 participants having fewer years of education com- 
001).
Statistically different from CDR 0 ( 2 2 = 11.93, P = .003). ¶Due to concerns about potential ceiling effects, differences in MMSE scores across the CDR groups were also tested using the nonparametric Kruskall-Wallis test. This test confirmed significant differences between the CDR 0 and the CDR 0.5 ( pared with the CDR 0 and 0.5 groups; (2) mean MiniMental State Examination scores, with the CDR 0.5 group lower than the CDR 0 group and the CDR 1 group lower than both the CDR 0 and 0.5 groups; and (3) sex distribution, with women composing 69% of the CDR 0 group and 42% and 50% of the CDR 0.5 and 1 groups, respectively. The CDR 0.5 and 1 groups together form the earlystage AD group with an APOE ε4 allele frequency of 57%, a proportion comparable with other studies.
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CSF AND PLASMA MARKERS AS A FUNCTION OF CLINICAL DIAGNOSIS
We examined whether levels of candidate markers (A␤ 40 , A␤ 42 , tau, and ptau 181 ) differed among the CDR groups. In unadjusted comparisons, CSF levels of A␤ 42 were significantly lower, and levels of tau and ptau 181 were significantly higher, in each of the early-stage AD groups (CDR 0.5 and 1) compared with the nondemented group ( Figure 1 and Table 2 Because sex, education, and APOE genotype distributions are different among the CDR groups (Table 1) , we next adjusted for and simultaneously tested the effect of these demographic variables together with CDR on each of the biomarker measures using general linear models. Education and APOE genotype were not associated with any of the biomarker measures in this elderly cohort. Sex, however, related to some of the biomarker effects. We also observed several complex 2-and 3-way interactions (between CDR, sex, and APOE genotype). The reliability and/or biological significance of these sex effects and complex interactions, if any, remain to be determined. Age and APOE genotype effects on CSF A␤ 42 levels in nondemented individuals have recently been reported 16 ; however, differences in the mean±SD age of subjects in that study compared with the present study (50±20 years vs 73.3±8.4 years, respectively) make it difficult to compare the 2 results. Of note, in analyzing a cohort of cognitively normal individuals including those of younger ages (45-90 years), we too observe a decrease in the CSF A␤ 42 level in individuals with the APOE ε4 allele as seen by Peskind et al 16 (A.M.F. and D.M.H., unpublished data, 2006). We observed no differences in the mean levels of plasma A␤ 40 and A␤ 42 (Figure 1) or the A␤ 40 /A␤ 42 ratio among the CDR groups (Table 2) , which is consistent with results from a previous study. 17 Cerebrospinal fluid tau/A␤ 42 and ptau 181 /A␤ 42 ratios, the most promising potential discriminators of clinical diagnosis, were assessed for their sensitivity and specificity. Receiver operating characteristic curves assessed the accuracy of these measures in classifying the presence (CDR 0.5 or CDR 1) vs absence (CDR 0) of dementia. The areas under the curve in these analyses were 0.79 (95% confidence interval [CI], 0.71-0.87) for the tau/A␤ 42 ratio and 0.73 (95% CI, 0.65-0.82) for the ptau 181 /A␤ 42 ratio, values considered to be acceptable but not impressive.
UTILITY OF CSF A␤ 42 LEVELS AND TAU/A␤ 42 AND PTAU 181 /A␤ 42 RATIOS FOR IDENTIFYING INDIVIDUALS WITH CORTICAL AMYLOID DEPOSITION
We used the new technique of in vivo brain amyloid imaging via PIB positron emission tomography 7, 8 to evaluate the ability of A␤ 42 -related CSF measures to discriminate individuals with amyloid plaques from those without plaques, regardless of clinical diagnosis. We recently reported an inverse relation between CSF A␤ 42 level and in vivo brain amyloid load in a small cohort of nondemented and mildly demented individuals. 7 We now have 50 individuals with both PIB and CSF measures in the present cohort. Individuals with positive binding (PIBϩ) displayed low levels of CSF A␤ 42 within their clinical group (Figure 2A) and high ratios of tau/A␤ 42 ( Figure 2B ) and ptau 181 /A␤ 42 ( Figure 2C ) compared with PIB-negative (PIB−) individuals, regardless of clinical diagnosis. Every subject in this cohort with CSF A␤ 42 levels lower than 457 pg/mL was PIBϩ, and every subject with CSF A␤ 42 of 457 pg/mL or greater was PIB−. In contrast, plasma A␤ 42 levels did not accurately identify PIBϩ vs PIB− individuals ( Figure 2D ).
ABILITY OF CSF MEASURES TO PREDICT FUTURE DEMENTIA IN NONDEMENTED ELDERS
Cerebrospinal fluid levels of tau, ptau 181 , and A␤ 42 appear useful in predicting further cognitive decline in individuals with mild cognitive impairment. [18] [19] [20] To our knowledge, the ability of these or other candidate markers to predict future cognitive decline or dementia in individuals who are still cognitively normal has not been assessed. We investigated whether demographic or biomarker measures influenced the rate of conversion from cognitively normal (CDR 0) to very mildly or mildly demented (CDRϾ0). Imaging with PIB was not performed on these individuals because this technique has become available only recently. For this analysis, we included data from cognitively normal elders (Ն60 years old) for whom there were 1 or more follow-up annual cognitive assessments. Of the 61 participants meeting these criteria, 13 (21%) had 1 or more CDRs of 0.5 or greater at follow-up, which averaged 3 to 4 years. This rate of dementia development in nondemented elders is consistent with population-based reports. 21 Individuals who went from CDR 0 to CDR greater than 0 were classified as converters, and those remaining CDR 0 at follow-up were considered nonconverters. Group demographics are described in Table 3 . Demographic variables did not differ between the 2 groups, except converters had significantly fewer years of formal education than nonconverters, and a greater percentage of women than men converted during follow-up in this small cohort.
Cox proportional hazard models revealed that education and CSF tau/A␤ 42 and ptau 181 /A␤ 42 measures significantly predicted conversion from CDR 0 to CDR greater than 0 ( For illustrative purposes, Kaplan-Meier estimates of rate of conversion from CDR 0 to CDR greater than 0 using tau/A␤ 42 and ptau 181 /A␤ 42 ratios as predictors are shown in Figure 3 . Individuals with high tau/A␤ 42 ratios (Ն1.15, corresponding to the top 15% of all values) were faster to display cognitive impairments (ie, CDRϾ0) compared with the remainder of the cohort (Ͻ1.15, corresponding to the bottom 85% of tau/A␤ 42 values) ( Figure 3A) . A similar pattern was observed for the CSF ptau 181 /A␤ 42 ratio (using Ն0.214 as the 15% cut-off ) ( Figure 3B A␤ 42 show strong promise as predictive biomarkers for future cognitive impairment in cognitively normal older adults. In addition, the finding that ratios of CSF tau/ A␤ 42 and ptau 181 /A␤ 42 , but not A␤ 42 levels alone, predicted conversion from CDR 0 to CDR greater than 0 over this short period suggests that increases in CSF tau levels occur after decreases in CSF A␤ 42 levels and herald the onset of dementia.
COMMENT
Increased life expectancy, coupled with potential diseasemodifying therapies currently in clinical trials, has shifted the goal of AD biomarker discovery from simply confirming a probable clinical diagnosis to identifying individuals with preclinical AD prior to any cognitive symptoms. A number of issues remain to be addressed. The generalizability of our findings is unclear since ours is a research study, not a population-based study, with limited racial and ethnic diversity. In addition, neuropathologic confirmation of disease will permit more accurate assessment of biomarker sensitivity and specificity. Finally, regarding the critical search for antecedent biomarkers, longer longitudinal follow-up of nondemented participants will provide a more accurate estimate of biomarker predictive value, and evaluation of even younger cohorts (age Ͻ60 years) 24 will address how early in the disease course such biomarker changes can be detected.
CONCLUSIONS
The number of individuals with AD dementia will increase dramatically over the next generation if effective therapies are not developed. Promising therapeutic candidates, some of which are potentially disease modifying, are on the horizon. Having CSF or other markers that predict future cognitive decline in individuals while they are still cognitively normal will help minimize the co- 
